In one paragraphArticle in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Maria Lucas-Parra *Cerebrovascular Pathology Research Group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Parc Hospitalari Martí i Julià, Edifici M2, Salt, 17190, Spain.ORCID http://orcid.org/0000-0002-2796-6732 Carme Gubern-Mérida *Cerebrovascular Pathology Research Group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Parc Hospitalari Martí i Julià, Edifici M2, Salt, 17190, Spain.ORCID http://orcid.org/0000-0001-8378-4477 Sofia DávilaMedical student, University of Girona (UdG), Emili Grahit, 77, Girona, 17003, Spain.
Tomàs Xuclà-FerraronsStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-2986-5038 Saima BashirStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-2019-467X Alan MurilloStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-1818-3736 Víctor Vera-MongeStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-7039-7440 Juan Álvarez-CienfuegosStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0003-1604-2179 Laia Carballo-PerichCerebrovascular Pathology Research Group, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Parc Hospitalari Martí i Julià, Edifici M2, Salt, 17190, Spain.ORCID http://orcid.org/0000-0002-1843-7660 Elisabet OrtizStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-1917-6132 Isabel Vielba-GomezStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.
Joaquín SerenaStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-4478-7744 Mikel TerceñoStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain. mterceno.girona.ics@gencat.cat.ORCID http://orcid.org/0000-0001-5532-5329 Yolanda SilvaStroke Unit, Department of Neurology, Cerebrovascular Pathology Research Group, University Hospital Doctor Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI-CERCA), RICORS-ICTUS, Av. França s/n (7a planta), Girona, 17007, Spain.ORCID http://orcid.org/0000-0002-9450-8918 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Inflammation contributes to haematoma expansion (HE) and poor prognosis in spontaneous intracerebral haemorrhage (ICH). This study aimed to characterise the temporal profile of soluble Toll-like receptor 4 (sTLR4) during the hyperacute and acute phases of ICH and to evaluate its association with HE. Serum sTLR4 levels were measured at admission, 24 and 72 h from 99 patients with primary hemispheric ICH within 12 h of symptom onset, and at baseline from 39 non-stroke controls using enzyme-linked immunosorbent assay (ELISA). Longitudinal sTLR4 fluctuations were evaluated through linear mixed-effects models. Independent HE prognosticators were identified using multivariable logistic regression, and model performance was assessed via the area under the receiver operating characteristic curve (AUC-ROC). ICH patients exhibited significantly higher baseline sTLR4 levels than controls, which declined over time and were not associated with clinical variables. Notably, patients with HE demonstrated higher admission sTLR4 levels than those without HE (2.50 [95% CI: 1.84-3.16] vs. 1.62 [95% CI: 1.22-2.02] ng/mL, p = 0.027). Furthermore, while the non-HE group showed a rapid decrease within the first 24 h, the HE group maintained elevated levels with a more gradual decline. A multivariable model incorporating baseline ICH volume and sTLR4 levels achieved an AUC of 0.829, with positive and negative predictive values of 70.8% and 90.1%, respectively. These findings suggest that TLR4 may be involved in the pathophysiology of HE, and the combination of baseline ICH volume and sTLR4 levels could serve as a useful tool to stratify patients into low- and high-risk groups for HE.
Indexed as
Cerebral HemorrhageToll-Like Receptor 4AgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosisROC CurveBiomarkersTLR4 protein, humanToll-Like Receptor 4BiomarkersHaematoma expansionIntracerebral haemorrhagePrognosisSoluble toll-like receptor 4
Identifiers
PMID42474911
PMCPMC13385087
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390